AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

AngioDynamics reports robust Q2 growth driven by key products

AngioDynamics delivered strong financial results driven by key product growth, reaffirming confidence in guidance and market stability.
Strategic focus on innovation, clinical trials, and global expansion positions the company for long-term success and market leadership.
Challenges in certain business segments require attention, but opportunities in new product releases and market expansion offer growth potential.
Overall, AngioDynamics remains committed to platform technologies and being a trusted care delivery partner, ensuring a strong strategic position in the market.

AngioDynamics reports Q3 growth, navigates challenges, eyes new opportunities

AngioDynamics showed solid revenue growth in Q3 2023, led by the Med Tech segment despite challenges with AngioVac.
The company is focused on addressing sales declines, exploring new product potentials, and maintaining cash flow neutrality.
Opportunities lie in new product usage trends, potential market expansions, and commitment to growth and profitability globally.
Despite revised guidance, AngioDynamics remains resilient in navigating challenges and pursuing strategic opportunities for future growth.

AngioDynamics posts solid earnings, eyes growth through innovation and markets

AngioDynamics delivered strong financial performance in Q4 2023 and FY '23, driven by growth in key segments and international markets.
The company's strategic focus on core businesses and favorable legal outcomes position it for future growth.
Challenges include projected losses for FY '24 and the need to boost Med Device revenue growth.
Opportunities lie in product innovation, clinical study outcomes, and market expansion initiatives.

AngioDynamics reports Q1 growth, eyes innovation amid investor concerns

AngioDynamics' Q1 performance reflects mixed results with revenue growth but losses per share, driven by strong segments like NanoKnife.
The company's financial position remains stable with healthy cash reserves and a positive outlook for future cash flow and revenue growth.
Challenges lie in balancing declining segments like mechanical thrombectomy with growth opportunities in new treatment areas and investor relations.
Opportunities for growth exist through innovation in the Auryon platform, potential indications from the APEX PE study, and strategic investor engagement.
AngioDynamics navigates a complex landscape of growth and challenges, focusing on innovation and financial stability amidst investor concerns.

AngioDynamics reports Q2 growth, navigates challenges with strategic initiatives

AngioDynamics delivered steady revenue growth in Q2 2024, driven by international expansion and strong performance in key segments.
While facing challenges in certain businesses, the company is strategically restructuring operations and investing in innovation for future growth.
Opportunities lie in expanding Auryon's market reach, optimizing manufacturing processes, and maintaining a focus on cost efficiency.
Overall, AngioDynamics is navigating challenges while positioning itself for long-term success through strategic initiatives and product enhancements.

AngioDynamics reports strong Q3 growth, eyes global expansion opportunities

AngioDynamics demonstrated solid revenue growth and strategic milestones in Q3 2024, with a focus on product innovation and international expansion.
While facing challenges in certain business segments, the company's regulatory successes and financial stability position it well for future growth.
Opportunities in upcoming data releases and market trends present avenues for AngioDynamics to capitalize on its strengths and drive further success.

AngioDynamics reports Q4 growth, eyes revenue expansion in 2025

AngioDynamics delivered a mixed performance in Q4 2024 with growth in Med Tech segment but declines in mechanical thrombectomy and Med Device segments.
Despite challenges, the company managed to generate excess cash flow and narrow its adjusted EBITDA loss, showcasing financial resilience.
Future opportunities lie in revenue growth projections for fiscal year 2025 and strategic initiatives aimed at market expansion and optimization.

AngioDynamics reports modest revenue growth and progresses towards profitability

AngioDynamics demonstrated overall growth in revenue and progress towards profitability in Q1 2025. While facing challenges with NanoKnife revenue and profitability, the company's Med Tech segment showed strength with Auryon and AlphaVac. Opportunities lie in cost savings from outsourced manufacturing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the second quarter of fiscal year 2022, which ended November 30, 2021. “We are pleased with our continued strong revenue growth as our team navigates this dynamic macro environment and manages through persistent COVID headwinds,” commented Jim Clemmer, Presiden

AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 24th Annual Needham Virtual Growth Conference at 2:00 p.m. ET on Monday, January 10, 2022. A live webcast of the presentation wi

AngioDynamics to Present at the Needham Virtual Growth Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market open on Thursday, January 6, 2022. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial

AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022

The medical devices company beat analyst expectations in the first quarter of its new fiscal year. Could it be a buy?

Is This Under-the-Radar Medical Devices Stock a Buy?

AngioDynamics Inc  (NASDAQ: ANGO) reported a Q1 FY22 adjusted EPS loss of $(0.02), ahead of the consensus of $(0.04). Q1 sales increased 9.6% Y/Y to $77 million, beating the analyst consensus of $71.31 million.

Investors Cheer AngioDynamics' Q1 Beat, Raised FY22 Sales Outlook

AngioDynamics, Inc.'s (ANGO) CEO Jim Clemmer on Q1 2022 Results - Earnings Call Transcript

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the first quarter of fiscal year 2022, which ended August 31, 2021. “We had a solid first quarter, and our team continues to deliver strong revenue performance and invest in our growth drivers while advancing our ongoing transformation,” commented Jim Clemmer,

AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of fiscal year 2022 before the market open on Thursday, September 30, 2021. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, di

AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

Why Is AngioDynamics (ANGO) Up 2.3% Since Last Earnings Report?

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 41st Annual Canaccord Genuity Virtual Growth Conference at 9:00 a.m. ET on Wednesday, August 11, 2021. A live webcast of the pre

AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference

AngioDynamics exceeded analyst expectations on revenue in Q4 2021, but does that make it worth buying?

After Beating Estimates, Is This Little-Known Medical Device Company a Buy?

AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.

AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q4 2021 Results - Earnings Call Transcript

AngioDynamics Inc (NASDAQ: ANGO) reports break-even in 4Q of 2021 with adjusted EPS of $0.00, a turnaround from EPS of (0.06) posted a year ago. The Company witnessed the pressure from COVID-19 gradually alleviate over the year, and business is now trending close to normalized run rates.

AngioDynamics Breaks-Even In FY21, Issues Mixed Forecasts For FY22

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the fourth quarter and fiscal year 2021, which ended May 31, 2021. “The AngioDynamics team demonstrated excellent performance, resilience, and strong execution in what was a uniquely challenging year. We saw the pressure from COVID-19 gradually alleviate over t

AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will host its Investor & Technology Day on Tuesday, July 13, from 9:30 a.m. to approximately 11:30 a.m. ET, which will include a question-and-answer session. The event, to be held virtually, will include presentations from AngioDynamics' executive leadership team. The Co

AngioDynamics Announces Details for Investor & Technology Day on July 13, 2021

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2021 before the market open on Tuesday, July 13, 2021. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial 1

AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day on July 13, 2021

AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.

AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?

AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.

AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the AlphaVac Mechanical Thrombectomy System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the non-surgical removal of thrombi or emboli from the vascula

AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference at 12:00 p.m. ET on Tuesday, May 25, 2021. A live webcast of the presentation will be accessible through the “Investors” section of the Company's website at www.angi

AngioDynamics to Present at the UBS Virtual Global Healthcare Conference

AngioDynamics (ANGO) Up 4.3% Since Last Earnings Report: Can It Continue?

Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.

Why You Should Hold AngioDynamics (ANGO) in Your Portfolio

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology today announced that on April 9, 2021, it submitted a 510(k) application to the United States Food and Drug Administration (FDA) for the AlphaVac System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the treatment of undesirable intravascular material in the venous syst

AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q3.

News for AngioDynamics Stock (ANGO)